ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients

Jiang, Shuai; Geng, Shuai; Chen, Qian; Zhang, Chen; Cheng, Mengfei; Yu, Yang; Zhang, Shuo; Shi, Ning*; Dong, Mei*哈尔滨医科大学
Frontiers in Oncology2022-2-9DOI: 10.3389/fonc.2022.823705
15被引12阅读
引用收藏
分享

摘要

Objective: Immune checkpoint inhibitors (ICIs) have changed the outcomes of a variety of cancers in an unprecedented manner. Gut microbiome plays a crucial regulatory role in the antineoplastic therapy of ICIs, which can be influenced by antibiotic (ABX) administration. In this efficacy evaluation, we aimed to clarify the correlations of ABX administration with the survival of cancer patients receiving ICIs treatment. @@@ Method: The eligible literatures were searched using PubMed, Cochrane Library, Web of Science, and Clinical trials.gov databases before Nov 2021. The correlations of ABX administration with progression-free survival (PFS) and overall survival (OS) were determined using Hazard ratios (HRs) coupled with 95% confidence intervals (CIs). @@@ Results: A total of 12 studies enrolling 6010 cancer patients receiving ICIs treatment were included in this efficacy evaluation. ABX administration was significantly correlated worse PFS (HR=1.60, 95%CI=1.33-1.92, P < 0.00001) and OS (HR=1.46, 95%CI=1.32-1.61, P < 0.00001). Similar results were found in the subgroup analysis of non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma. @@@ Conclusions: ABX use during ICIs treatment of cancer may significantly shorten PFS and OS. ABX should be used cautiously in cancer patients receiving ICIs. However, further validations are still essential due to existing publication bias.

学科与关键词

关键词
cancerimmune checkpoint inhibitors (ICIs)antibioticsprogression-free survival (PFS)overall survival (OS)
相关
加载中…
  • Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs
    Yu, Jiuhang; Yin, Yichuang; Yu, Yang; Cheng, Mengfei; Zhang, Shuo; Jiang, Shuai*; Dong, Mei*Immunopharmacology and Immunotoxicology, 2023, 45(3): 386-394.被引 3
  • The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review
    Chen, Jixin; Chen, Shuqi; Luo, Huiyan; Long, Shunqin; Yang, Xiaobing; He, Wenfeng; Wu, Wanyin*; Wang, Sumei*International Immunopharmacology, 2023, 124: 110919.被引 1
  • Gold digging: Searching for gut microbiota that enhances antitumor immunity
    Hou, Fengyi; Pan, Zhiyuan; Yang, Ruifu; Zhi, Fachao*; Bi, Yujing*Journal of Cellular Physiology, 2021, 236(8): 5495-5511.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-02-09
卷期
第 12 卷
页码
823705
DOI
10.3389/fonc.2022.823705
期刊等级
3区
成果收录
SCIE
资助标注
Key Program of Harbin Medical University Cancer Hospital Haiyan Fund [JJZD2019-03]; General Program of Harbin Medical University Cancer Hospital Haiyan Fund [JJMS2021-25]

作者

  • J

    Jiang, Shuai (第一作者)

    harbin med univ

  • G

    Geng, Shuai

查看全部 9 位作者收起作者
  • C

    Chen, Qian

  • Z

    Zhang, Chen

  • C

    Cheng, Mengfei

    harbin med univ

  • Y

    Yu, Yang

    harbin med univ

  • Z

    Zhang, Shuo

    harbin med univ

  • S

    Shi, Ning (通讯)

  • D

    Dong, Mei (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417